tetano
Editor, Senior Moderator
Euro Surveill. 2018 Feb;23(8). doi: 10.2807/1560-7917.ES.2018.23.8.18-00062.
[h=1]Interim estimate of influenza vaccine effectiveness in hospitalised children, Hong Kong, 2017/18.[/h] Chiu SS[SUP]1,[/SUP][SUP]2[/SUP], Kwan MYW[SUP]3,[/SUP][SUP]1[/SUP], Feng S[SUP]4[/SUP], Wong JSC[SUP]3[/SUP], Leung CW[SUP]3[/SUP], Chan ELY[SUP]2[/SUP], Peiris JSM[SUP]5,[/SUP][SUP]4[/SUP], Cowling BJ[SUP]4[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] We conducted a hospital-based test-negative study in Hong Kong to estimate influenza vaccine effectiveness (VE) for the winter of 2017/18. The interim analysis included data on 1,078 children admitted between 4 December 2017 and 31 January 2018 with febrile acute respiratory illness and tested for influenza. We estimated influenza VE at 66% (95% confidence interval (CI): 43-79) overall, and 65% (95% CI: 40-80) against influenza B, the dominant virus type (predominantly B/Yamagata).
[h=4]KEYWORDS:[/h] influenza virus; public health; test negative design; vaccine effectiveness; vaccines and immunisation; viral infections
PMID: 29486830 DOI: 10.2807/1560-7917.ES.2018.23.8.18-00062
[h=1]Interim estimate of influenza vaccine effectiveness in hospitalised children, Hong Kong, 2017/18.[/h] Chiu SS[SUP]1,[/SUP][SUP]2[/SUP], Kwan MYW[SUP]3,[/SUP][SUP]1[/SUP], Feng S[SUP]4[/SUP], Wong JSC[SUP]3[/SUP], Leung CW[SUP]3[/SUP], Chan ELY[SUP]2[/SUP], Peiris JSM[SUP]5,[/SUP][SUP]4[/SUP], Cowling BJ[SUP]4[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] We conducted a hospital-based test-negative study in Hong Kong to estimate influenza vaccine effectiveness (VE) for the winter of 2017/18. The interim analysis included data on 1,078 children admitted between 4 December 2017 and 31 January 2018 with febrile acute respiratory illness and tested for influenza. We estimated influenza VE at 66% (95% confidence interval (CI): 43-79) overall, and 65% (95% CI: 40-80) against influenza B, the dominant virus type (predominantly B/Yamagata).
[h=4]KEYWORDS:[/h] influenza virus; public health; test negative design; vaccine effectiveness; vaccines and immunisation; viral infections
PMID: 29486830 DOI: 10.2807/1560-7917.ES.2018.23.8.18-00062